TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16604826
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg daily for 5 days)
Study: 10748791
Drug: Beta-blocker treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker treatment (Bisoprolol)
Study: 2123239
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with penicillin V (10-day course starting at diagnosis)
Study: 2123239
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with penicillin V (10-day course starting after 48 hours)
Study: 6104858
Drug: tiapride (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapride (300 mg daily for 3-4 weeks)
Study: 6104858
Drug: floctafenine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: floctafenine (200 mg daily for 3-4 weeks)
Study: 20638874
Drug: Melatonin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin infusion (50 mg IV during surgery) and oral melatonin (10 mg for 3 nights post-surgery)
Study: 20638874
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion and oral placebo
Study: 15746463
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg per day
Study: 10480207
Drug: Vigabatrin (GVG)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (GVG) therapy
Study: 2300680
Drug: Moclobemide (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (100, 200, and 300 mg)
Study: 2300680
Drug: Deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl (10 mg)
Study: 31942627
Drug: Darunavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir 800/100 mg q24h with rifampicin, escalated to darunavir/ritonavir 1600/200 mg q24h and 800/100 mg q12h.
Study: 31942627
Drug: Darunavir/ritonavir adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir adjusted doses with rifampicin.
Study: 22572824
Drug: Long-acting octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting octreotide (Sandostatin LAR®) depot 30 mg intramuscularly every month
Study: 20500927
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg quercetin/d
Study: 20500927
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg quercetin/d
Study: 17971108
Drug: Nicorette polacrilex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorette polacrilex gum (6 mg)
Study: 12433727
Drug: Selenium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched yeast supplementation (247 micro g selenium/day)
Study: 7669482
Drug: Fluparoxan (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluparoxan (twice-daily for 5 1/2 days, 11 doses)
Study: 2161038
Drug: WI79-9 vaccine
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WI79-9 vaccine (10^7.3 plaque-forming units/dose, 2 doses, 28 days apart)
Study: 2161038
Drug: WI79-9 vaccine
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WI79-9 vaccine
Study: 26421702
Drug: Intravenous 50
Normalized name: immune globulin intravenous 50 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 50 μg bolus of phenylephrine (Group P)
Study: 19713403
Drug: Humidification therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidification therapy techniques (specific techniques not detailed in the abstract)
Study: 11535941
Drug: Clobazam and
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam and tramadol administration
Study: 7817819
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a dosage of 0.2 IU/kg/day for 3 days
Study: 29980162
Drug: Home based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home based electrostimulation therapy (EST) with amplitude modulated current (base frequency of 4000 Hz, frequency band of 100–250 Hz) over 2 weeks adjuvant to a concurrent sinusitis therapy with topical corticosteroids
Study: 23212807
Drug: High-dose risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose risperidone (1.25 mg/day for 20 to <45 kg; 1.75 mg/day for >45 kg)
Study: 23212807
Drug: Low-dose risperidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose risperidone (0.125 mg/day for 20 to <45 kg; 0.175 mg/day for >45 kg)
Study: 23212807
Drug: High-dose risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose risperidone
Study: 21178989
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg sustained-release dextroamphetamine (d-AMP)
Study: 1986555
Drug: Corticosteroids (15-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (15-day tapering dose of prednisone: 15, 10, 5 mg) with diuretics (40 mg furosemide and 200 mg spironolactone)
Study: 1986555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diuretics only: 40 mg furosemide and 200 mg spironolactone)
Study: 6851752
Drug: Combined bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bowel lavage and parenteral antibiotic prophylaxis with 4 gm Cefoxitin (group II)
Study: 10924317
Drug: Amiodarone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (5 mg. kg(‐1))
Study: 8825017
Drug: Broad spectrum
Normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Broad spectrum antioxidant capsule (po BID)
Study: 2998191
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg of terodiline daily for two 3-week periods
Study: 2998191
Drug: Long-term terodiline
Normalized name: terodiline
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term terodiline treatment (6 months to 3 years)
Study: 2998191
Drug: Terodiline treatment
Normalized name: terodiline
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terodiline treatment
Study: 29890960
Drug: Mentalisation-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalisation-based treatment (MBT)
Study: 30058839
Drug: 5-mg axitinib
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg axitinib
Study: 30058839
Drug: 400-mg sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-mg sorafenib
Study: 29164749
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) of calf muscles, twice a week for six weeks (3 × 6 stimulation trains at 30 Hz above individual cramp threshold frequency)
Study: 24368315
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran extract (WBE) at 5.0 g/day for 3 weeks
Study: 24368315
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g/day WBE)
Study: 20498613
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (music-based imagery and music alternate engagement)
Study: 25550337
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg abatacept
Study: 10626341
Drug: Sinopril (lisinopril)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sinopril (lisinopril) 10-40 mg daily for 8 weeks
Study: 10626341
Drug: Captopril (capoten)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (capoten) 25-100 mg daily for 8 weeks
Study: 10626341
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Sinopril and Captopril)
Study: 7540856
Drug: rhGM-CSF at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF at 10 micrograms/kg/d after cyclophosphamide 4 g/m2 i.v.
Study: 7540856
Drug: rhG-CSF at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG-CSF at 10 micrograms/kg/d after cyclophosphamide 4 g/m2 i.v.
Study: 6259740
Drug: Protocol A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A: surgery + chemotherapy alone (60 patients)
Study: 6259740
Drug: Protocol B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B: surgery + radiotherapy + chemotherapy (22 patients)
Study: 6259740
Drug: Protocol C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C: surgery + chemotherapy (4 cycles) + radiotherapy + chemotherapy (51 patients)
Study: 31100756
Drug: Homeopathic medicines
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicines prescribed with consideration of individual temperament (temperament(+))
Study: 31100756
Drug: Homeopathic medicines
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicines prescribed without consideration of individual temperament (temperament(-))
Study: 21146420
Drug: 30 deep
Normalized name: ZINC OXIDE 940 mg in 1 mL TOPICAL LIQUID [Crunchi Sunlight Tinted Sunscreen SPF 30 Deep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 deep breaths hourly
Study: 21146420
Drug: 10 deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 deep breaths hourly
Study: 19693752
Drug: Anticholinergic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic treatment (Tolterodin)
Study: 15662902
Drug: Guideline recommendations
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline recommendations for the diagnosis, treatment, and management of infectious endocarditis
Study: 9487784
Drug: Computer-administered version
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered version of the Freiburg Personality Inventory (FPI-R)
Study: 8267694
Drug: Hyperimmune globulin
Normalized name: Anti-COVID-19 hyperimmune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmune globulin (HIg) prophylaxis administered from week 1 until week 7 after transplantation
Study: 18834364
Drug: Piroxicam-beta-cyclodextrin sachets
Normalized name: piroxicam-beta-cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam-beta-cyclodextrin sachets (20 mg daily for 28 days)
Study: 18834364
Drug: Piroxicam tablets
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam tablets (20 mg daily for 28 days)
Study: 18834364
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (sachet and tablets)
Study: 8029513
Drug: topical zinc
Normalized name: bacitracin topical zinc compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical zinc ointment
Study: 2532461
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 to 5 mg once daily
Study: 30965072
Drug: Standardized music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized music therapy (MT) for 15 minutes prior to EEG session (Group 2)
Study: 30965072
Drug: Standardized music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized music therapy (MT) for 15 minutes prior to EEG session plus rubber cap for home practice (Group 3)
Study: 30965072
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (Group 1)
Study: 30965072
Drug: Standardized music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized music therapy (MT) procedural support during EEG session for all groups
Study: 25066733
Drug: IV n-3PUFA
Normalized name: (+/-)-N-methylephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV n-3PUFA emulsion (0.6 g/kg body weight)
Study: 25066733
Drug: Oral n-3PUFA
Normalized name: N'ICE Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral n-3PUFA (0.6 g/kg over 3 consecutive days)
Study: 21399726
Drug: Valerian officinalis
Normalized name: Valeriana officinalis whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian officinalis 450 mg orally 1 hour before bedtime for 8 weeks
Study: 21399726
Drug: Valerian officinalis
Normalized name: Valeriana officinalis whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian officinalis 450 mg
Study: 18562424
Drug: Venlafaxine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (average dose 103.5 mg/day)
Study: 18562424
Drug: Tricyclic Antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic Antidepressants (TCAs) (average dose 106.1 mg/day)
Study: 17039666
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of apple polyphenols
Study: 17039666
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of apple polyphenols
Study: 14701886
Drug: Integrated management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated management approach (early clinical review, education sessions, personal diary for medications and weight, regular clinical follow-up alternating between GP and hospital clinic)
Study: 10688389
Drug: nabumetone 2000
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nabumetone 2000 mg/d
Study: 10688389
Drug: naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 1000 mg/d
Study: 9357406
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (2 g bolus, followed by 8 g over 24 h)
Study: 28283760
Drug: Shiatsu (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shiatsu (alone or in combination)
Study: 14695733
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg intravenous M6G
Study: 9863106
Drug: Positive drug
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive drug Juhong Tanke Ye control group
Study: 15683433
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg b.i.d.
Study: 2877912
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg b.i.d.
Study: 3075106
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg nocte.
Study: 3075106
Drug: Famotidine single
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine single 20 mg bedtime dose.
Study: 3075106
Drug: Ranitidine (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (dosage not specified).
Study: 26396163
Drug: Creative art
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative art therapy plus conventional physical therapy
Study: 31027060
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy only
Study: 23906869
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (2.0g in 75mL of normal saline)
Study: 17625502
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg q.d. for 6 weeks then 10 mg q.d. for 6 weeks
Study: 14638485
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of artemether
Study: 14638485
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of artemether
Study: 1602030
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training as an adjunct to radiation therapy (34 patients)
Study: 1602030
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and counseling along with radiation therapy (29 patients)
Study: 31449472
Drug: Antivirals within
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antivirals within 3 days pre‐BAL
Study: 26613389
Drug: L-methylfolate calcium
Normalized name: L-Methylfolate Calcium
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-methylfolate calcium (15 mg/d)
Study: 19220676
Drug: i.v. imipenem-cilastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. imipenem-cilastatin (3 x 500 mg/day) for 7-14 days
Study: 15515408
Drug: 5-HT3 receptor
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonist tropisetron
Study: 9027672
Drug: Transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerine patches delivering 0.2 or 0.1 mg/h, applied during the first 3 days of the menstrual cycle for up to three consecutive cycles
Study: 9027672
Drug: Transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerine patches
Study: 8319191
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous ondansetron with lorazepam and dexamethasone
Study: 8319191
Drug: Continuous-infusion metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion metoclopramide with lorazepam, dexamethasone, and diphenhydramine
Study: 26824379
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic nimodipine treatment
Study: 25020273
Drug: UMEC/VI 500/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI 500/100 μg
Study: 26366068
Drug: UMEC/VI 125/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI 125/25 μg
Study: 23569370
Drug: UMEC 500
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 500 μg
Study: 25020273
Drug: UMEC 500/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 500/100 μg
Study: 22133208
Drug: BUD/FM 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FM 160/4.5 μg × 2 inhalations bid
Study: 22133208
Drug: BUD 180
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD 180 μg × 2 inhalations bid
Study: 10210789
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment methods
Study: 16411785
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy interventions (including music and movement, active music listening, group chanting and singing, musical games, rhythmic training, music and sign language, and lyric analysis and rewrite activities)
Study: 16411785
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy interventions
Study: 10974446
Drug: Severely anemic
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severely anemic group (hemoglobin < 11.0 g/100 mL)
Study: 10974446
Drug: Non-anemic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anemic group (hemoglobin ≥ 11.0 g/100 mL)
Study: 10974446
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in mean blood hemoglobin value by 1 g/100 mL
Study: 8625547
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIG) treatment
Study: 6404979
Drug: Spironolactone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (400 mg for first 10 days, then 300-200 mg)
Study: 6404979
Drug: Spironolactone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (200 mg for the whole length of therapy)
Study: 27628221
Drug: Olmesartan added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan added to combination of ACEI and BB in HFrEF patients
Study: 31808984
Drug: Oral betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral betamethasone
Study: 17600286
Drug: peg‐IFN‐α2a 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐IFN‐α2a 180 mcg s.c. once weekly + Ribavirin 1000‐1200 mg p.o. daily + Tα1 1.6 mg s.c. twice weekly for 24 weeks
Study: 9698948
Drug: 0.15, 0.30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15, 0.30, or 0.45 mg/kg racemic ketamine
Study: 7869918
Drug: gemfibrozil (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (1,200 mg/d)
Study: 19965915
Drug: simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (10 mg/d)
Study: 2229837
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT) with birch‐pollen extract
Study: 6289661
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate
Study: 20055345
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (15 mg/kg)
Study: 12909471
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 20 parts per million
Study: 1997887
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and chloroethylnitrosoureas (methyl‐CCNU, 100‐120 mg/m2, or ACNU 80‐100 mg/m2, every 6‐8 weeks)